CAR T-Cell Immunotherapy is a new type of cancer treatment. This emerging treatment represents one of the biggest breakthroughs since the introduction of chemotherapy. T cells is a type of white blood cell extracted from the patient's blood by doctors, and added an artificial receptor to their surface. When infused into a patient, the cells get multiplied and stay in the body as "living drugs" and help in detecting and fighting cancer. CAR-T cell therapy is defined as a type of immunotherapy that teaches T cells to recognize and destroy cancer.

According to this study, over the next five years the CAR T-Cell Immunotherapy market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in CAR T-Cell Immunotherapy business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of CAR T-Cell Immunotherapy market by product type, application, key companies and key regions.

This study considers the CAR T-Cell Immunotherapy value generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Monotherapy
Combination Therapy
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hematologic Malignancies
Solid Malignancies

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
AbbVie
Celgene
Kite Pharma
Oxford BioMedica
Novartis
Gilead
Pfizer
Cellectis
Bellicum
Mustang Bio
CARsgen Therapeutics
Xyphos
Minerva Biotechnologies
Adaptimmune
Ziopharm Oncology
Aurora Biopharma
Creative Biolabs

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global CAR T-Cell Immunotherapy market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of CAR T-Cell Immunotherapy market by identifying its various subsegments.
Focuses on the key global CAR T-Cell Immunotherapy players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the CAR T-Cell Immunotherapy with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of CAR T-Cell Immunotherapy submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.